Macrogenics INC Form 4 insider transactions

Federica F. O'Brien, a Director at Macrogenics Inc., reported transactions involving common stock, restricted stock units, and stock options.

Macrogenics Inc. reports director Scott Jackson's transactions involving restricted stock units and stock options.

Macrogenics Director William K. Heiden reported transactions involving restricted stock units and stock options.

Jay Philip Siegel, a Director at Macrogenics Inc., reported a transaction involving 3,750 shares of common stock on May 18, 2026.

Director Margaret Liu reported a transaction involving Macrogenics Inc. common stock, acquiring 3,750 shares through vested Restricted Stock Units.

Director Meenu Chhabra reported transactions involving Macrogenics Inc. common stock, including the acquisition of restricted stock units and the disposal of common stock.

Director Edward Hurwitz of Macrogenics Inc. reported a transaction involving the acquisition of 3,750 shares of common stock.

David C. Stump, a Director at Macrogenics Inc., reported transactions involving restricted stock units and stock options.

Macrogenics Inc. reports director Karen Ferrante's transactions involving restricted stock units and stock options.

Director Scott Koenig of Macrogenics Inc. has acquired restricted stock units and stock options, indicating continued investment in the company.

Macrogenics Director Scott Koenig converted 15,831 restricted stock units into common stock, increasing his direct ownership.

Macrogenics Senior Vice President of Technical Operations, Thomas Spitznagel, exercised restricted stock units and sold a portion of the resulting common stock to cover tax obligations.

Macrogenics' VP, Controller & Treasurer, Beth Ann Smith, reported the vesting of restricted stock units and subsequent sale of shares for tax withholding purposes.

Macrogenics President and CEO Eric Risser exercised restricted stock units and subsequently sold a portion of the acquired shares to cover tax obligations.

Macrogenics Senior VP Jeffrey Peters reported the vesting of restricted stock units and subsequent sale of shares for tax purposes.

Macrogenics' SVP and CFO, James Karrels, reported the vesting of restricted stock units and subsequent sale of shares to cover tax obligations.

Macrogenics' Senior VP of Research and CSO, Ezio Bonvini, reported the conversion of restricted stock units into common stock and subsequent tax-related dispositions.

Macrogenics' VP, Controller & Treasurer, Beth Ann Smith, was granted 25,000 employee stock options with a $1.33 exercise price.

MacroGenics Director William K. Heiden increased his direct ownership in the company by acquiring 100,000 shares of common stock across two transactions in August 2025.

Macrogenics Inc. has granted 30,000 employee stock options to Senior VP of Technical Operations, Thomas Spitznagel, with an exercise price of $1.58.

Macrogenics Senior VP and General Counsel Jeffrey Stuart Peters was granted 30,000 employee stock options with an exercise price of $1.58.

Macrogenics Director Scott Koenig's restricted stock units vested following a separation and consulting agreement, resulting in the acquisition of 52,829 common shares.

Macrogenics Inc. President and CEO Eric Blasius Risser was granted 550,000 employee stock options with a $1.66 exercise price, vesting over four years.

Director Federica F. O'Brien reports acquisition of common stock, restricted stock units, and stock options in Macrogenics Inc.

Director Scott Thomas Jackson reports acquisition and disposal of Macrogenics Inc. stock and derivative securities.

Director William K. Heiden reports acquisition and disposal of MacroGenics stock and stock options.

Director David C. Stump reports acquisition and disposal of Macrogenics Inc. stock and derivative securities.

Director Karen Jean Ferrante reports acquisition and disposal of MacroGenics Inc. stock and derivative securities.

Director Margaret Liu reports acquisition of shares and restricted stock units in Macrogenics Inc.

Director Edward Hurwitz reports acquisition and disposal of Macrogenics stock and derivative securities.